![When communicating with patients, it is essential to provide them with key information about their drug regimen, including what the drug is, why they need it, when and how to take it, and for how long they need to take it. [6] They should also be educated about the fluctuating nature of RA, the consequences of nonadherence, and the potential adverse effects associated with their treatment so that they know what to expect and when to call for instruction, reducing the risk of them altering their regimen. [6,10] Because patients of lower socioeconomic status and ethnic minorities are at especially high risk of nonadherence, the RESPECT model of communicating, which has received recognition for improving cultural competence and overall rapport, might be especially beneficial in the RA setting. RESPECT comprises seven core elements: Respect (show), Explain (provide), Support (provide), Power (share), Empathy (show), Concerns (address), and Trust (build). [11]](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/5doctorchartcomputerts541_1041336-544x306.jpg)
Study authors highlighted the challenges associated with the identification of published COVID-19 literature and suggested resources for rheumatologists and their patients.
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.
The American College of Rheumatology updated its COVID-19 guidance for the management of adult patients with rheumatic diseases.
Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.
The American College of Rheumatology has issued a set of position statements for the use of telemedicine in the management of patients with rheumatic diseases.
Study leads Shilpa Venkatachalam, PhD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.
In this episode, we discuss the effect of the COVID-19 pandemic on the health of rheumatologists and how this may have an impact on delivering patient care.
Drug reaction with eosinophilia and systemic symptoms (DReSS) with exposure to interleukin-1 or interleukin-6 inhibition may be linked to high fatality lung disease in systemic juvenile idiopathic arthritis.
Doug Roberts, MD, discusses the effect that the novel coronavirus could have in patients who are immunocompromised with rheumatic diseases.
The European League Against Rheumatism developed recommendations for the collection, analysis, and use of big data in rheumatic and musculoskeletal disorders.
